As domestic pharmaceutical companies rush into the competitive GLP-1 weight-loss drug development market, a crack in the collaboration chain is quietly spreading. On September 5th, CRO company Shanghai Medicilon Inc. announced that its subsidiary Medicilon Primacy Biotech was sued by client Hongxu Biotech, with compensation claims reaching 159 million yuan, equivalent to 30% of Shanghai Medicilon Inc.'s total revenue in the first half of the year. This explosive lawsuit has exposed the fragile trust relationship between pharmaceutical companies and outsourcing service providers amid the innovative drug development boom.
**The R&D Conundrum Behind the Billion-Yuan Claim**
The dispute stems from a "Technical Service Contract" signed by both parties in 2020. Hongxu Biotech commissioned Medicilon Primacy to provide non-clinical safety evaluation services for its GLP-1/GIP dual-target new drug HX-100101-1 injection (benchmarking against Eli Lilly's tirzepatide), targeting dual filings in China and the US. The contract stipulated that Shanghai Medicilon Inc. needed to complete four trials within 8 months and submit Chinese and English reports. Hongxu Biotech accused Medicilon Primacy of serious breach of contract, demanding contract termination, refund of 5.018 million yuan in service fees, and claiming 3.515 million yuan in penalty fees plus 150 million yuan in losses. Notably, while the disputed project obtained China's clinical trial approval in December 2023, the National Medical Products Administration suddenly initiated a for-cause inspection at the end of March this year - this type of inspection targeting suspected data authenticity issues or tip-offs, though the announcement stated "no authenticity problems were found," hints at significant disagreements in the collaboration.
**Life-or-Death Test for the Mid-sized Giant**
For Shanghai Medicilon Inc., with annual revenue just exceeding the 1 billion yuan level, this lawsuit amounts to a survival stress test. If the court supports all of Hongxu's claims, the payment amount would far exceed the company's first-half net profit (-12.89 million yuan). While the secondary market responded calmly with a 4.69% gain on the announcement day, deeper crises have emerged: as a clinical-stage CRO positioned as "small but excellent," public client accusations of its contract fulfillment capabilities could shake the industry's trust foundation; even if the final compensation is discounted, the litigation process might trigger tightened client payment terms and delayed new orders; especially during the critical period of betting on metabolic drugs, disputes over flagship projects could affect acquisition of similar contracts.
**"Black Swan" on the Path to Turnaround**
This lawsuit casts a shadow over Shanghai Medicilon Inc.'s difficult recovery path. Financial reports show the company suffered continuous losses in 2023-2024, but signs of recovery emerged this year: first-half revenue reached 540 million yuan (+3.64%), overseas revenue surged 31% to 248 million yuan, and Q2 achieved quarterly turnaround. Shanghai Medicilon Inc. stands at a critical inflection point for recovery, and if the litigation drags on, its hard-won profitability recovery could be devoured again.
**Cracks Beneath CRO Prosperity**
The dispute has torn open industry concerns behind the innovative drug boom. As pharmaceutical companies frantically advance R&D to capture the GLP-1 track, the aggressive 8-month timeline to complete 4 safety evaluations reflects a distorted pursuit of R&D efficiency. While data authenticity issues in submission materials remain unconfirmed, the "for-cause inspection" warns of the prevalence of unclear responsibility delineation in collaborations.
Comments